Evidence map›Paper›PMID 33088688›Full record

ArticleActa pharmaceutica Sinica. B2020

Nonclinical safety, tolerance and pharmacodynamics evaluation for meplazumab treating chloroquine-resistant

Kun Zhang, Yu Zhao, Zheng Zhang, Mengyao Zhang, Xiaodong Wu, Huijie Bian, Ping Zhu, Zhinan Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kun ZhangCollege of Life Science and Bioengineering, School of Science, Beijing Jiaotong University, Beijing 100044, China.
Yu ZhaoNational Translational Science Center for Molecular Medicine & Department of Cell Biology, the Fourth Military Medical University, Xi'an 710032, China.
Zheng ZhangNational Translational Science Center for Molecular Medicine & Department of Cell Biology, the Fourth Military Medical University, Xi'an 710032, China.
Mengyao ZhangNational Translational Science Center for Molecular Medicine & Department of Cell Biology, the Fourth Military Medical University, Xi'an 710032, China.
Xiaodong WuNational Translational Science Center for Molecular Medicine & Department of Cell Biology, the Fourth Military Medical University, Xi'an 710032, China.
Huijie BianNational Translational Science Center for Molecular Medicine & Department of Cell Biology, the Fourth Military Medical University, Xi'an 710032, China.
Ping ZhuDepartment of Clinical Immunology, Xijing Hospital, the Fourth Military Medical University, Xi'an 710032, China.
Zhinan ChenCollege of Life Science and Bioengineering, School of Science, Beijing Jiaotong University, Beijing 100044, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Meplazumab is an anti-CD147 humanized IgG2 antibody. The purpose of this study was to characterize the nonclinical safety, tolerance and efficacy evaluation of meplazumab treating chloroquine resistant

Indexed as

ADA, anti-drug antibodyADCC, antibody-dependent cell-mediated cytotoxicityAntimalarial therapyCD147EfficacyFab, variable region of monoclonal antibodyFc, crystalline region of monoclonal antibodyFFPE, formalin-fixed paraffin-embeddedHPLC, high-performance liquid chromatographyHRP, horseradish peroxidasehuRBCs, human red blood cellsIR, inhibition ratemAbs, monoclonal antibodiesMeplazumabNOG mice, NOD/Shi-scid/IL-2Rγ null miceNonclinicalPBS, phosphate buffered salinePC50, median parasite clearance timePlasmodium falciparumPr, parasitemiaRAP2, rhoptry-associated protein 2RBCs, red blood cellsRH5, reticulocyte-binding protein homolog 5RO, receptor occupancySafetySD rats, Sprague–Dawley ratsTCA, trichloroacetic acidToleranceWHO, World Health Organization

Identifiers

PMID33088688
PMCPMC7564037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.